Epigenetic treatments: New allies for chemotherapies?

A research team¹ led by Celine Vallot, CNRS Research Director in the Laboratoire Dynamique de l'information Génétique: Bases Fondamentales et Cancer (CNRS/Institut Curie/Sorbonne Université), and the Département de Recherche Translationnelle de l'Institut Curie (CNRS/Institut Curie/Sorbonne University), analysed cell by cell the epigenetic variations acquired by tumour cells during chemotherapy treatment. In collaboration with the team of Léila Périé, a CNRS researcher at the Physico-chimie Curie (CNRS/Institut Curie/Sorbonne Université), the scientists identified the genes whose expression allowed cells to tolerate² treatment, as well as the epigenomic modifications that regulate them. Scientists have found that epigenomic marks "lock" the expression of these genes in the absence of treatment, and that this lock jumps under chemotherapy in rare cells. If this lock is prevented from jumping, all cancer cells remain sensitive to treatment. Scientists have demonstrated this by using chemical compounds called epi-drugs³ on animal models of breast cancer that inhibit the removal of epigenetic marks. These molecules still need to be adapted for human use.

These results clearly demonstrate the epigenome's involvement in resistance to cancer treatment. The scientists are now actively seeking how to apply this concept to humans from a therapeutic perspective. If future clinical trials are convincing, scientists imagine that these epi-treatments could be used in conjunction with chemotherapies to prolong their effectiveness in patients.